CIRB #H-42963\/ CTSU #A022001:<\/strong><\/strong><\/a> Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors<\/p>\n Advarra IRB #H-43892\/ RayzeBio RYZ101-301:<\/strong><\/a> Phase 1b\/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy<\/p>\n CIRB #H-43515\/ CTSU #A022104 (JANUS):<\/strong><\/a> The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing The Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients With Locally Advanced Rectal Cancer<\/p>\n CIRB #H-44177\/ NRG GI008 (CIRCULATE-NORTH AMERICA):<\/strong><\/a> Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease<\/p>\n Advarra IRB #H-45290\/ Takeda #TAK-113-4002:<\/strong><\/a> A Single Arm Phase 4 Trial to Evaluate the Safety and Efficacy of Oral Fruquintinib in the Treatment of Refractory Metastatic Colorectal Cancer in Patients from Minority Populations Underrepresented in Prior Fruquintinib Studies (pending IRB)<\/b><\/p>\n WCG IRB #H-43572\/ Genentech GO44479:<\/strong><\/a> A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma<\/p>\n CIRB #H-40808\/ CTSU #A021806:<\/strong><\/a> A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer<\/p>\n IRB #H-41225\/ Partners #Decision Aids:<\/strong><\/a> Development and Implementation of Electronic Decision Aids for Genetic Testing in Inherited Cancer Syndromes<\/p>\n CIRB H-43647\/ CTSU #A022102:<\/strong><\/a> Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma<\/p>\n WCG IRB #H-44285\/ Deciphera DCC-2618-03-003 (INSIGHT):<\/strong><\/a> An International, Phase 3, Randomized, Multicenter, Open-label Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With KIT Exon 11 and Co-occurring KIT Exons 17 and\/or 18 Mutations Who Were Previously Treated With Imatinib<\/p>\n Central IRB #H-44599\/ AstraZeneca #EMERALD-Y90:<\/strong><\/a> Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere™) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy<\/p>\n CIRB #H-45085\/ ETCTN #10608:<\/strong><\/a> A Phase II Trial of Durvalumab with Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma<\/p>\nColorectal:<\/h3>\n
Pancreatic:<\/h3>\n
Stomach\/Esophageal:<\/h3>\n
Liver\/Hepatobiliary:<\/h3>\n
Anal:<\/h3>\n